Rapid changes such as the launch of new biologic therapies and novel drugs, increasing number of patients, and advancements in imaging techniques to facilitate drug development will drive the osteoarthritis market to $10.5bn in value by 2024, says a report by GlobalData.

Titled ‘OpportunityAnalyzer: Osteoarthritis – Opportunity Analysis and Forecasts to 2024’, the report estimates the osteoarthritis market to witness a compound annual growth rate (CAGR) of 17.8% over the forecast period. The seven major markets considered for the forecast are the US, France, Germany, Italy, Spain, the UK, and Japan.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The report expects that new biologic therapies targeting the disease will be launched at a substantial premium to small-molecule therapies, unlike the inexpensive generic drugs being used for decades.

" … The osteoarthritis pipeline is rapidly evolving thanks to improved understanding of the disease’s pathophysiology and recent biomarker development."

Furthermore, available therapies target only the disease symptoms, while the need for biologic and disease-modifying therapies such as Invossa, a cell-based, disease-modifying osteoarthritis drug remains unmet, says Claire Herman, MPH, Global Director of Therapy Analysis and Epidemiology at GlobalData.

“Despite this, the osteoarthritis pipeline is rapidly evolving thanks to improved understanding of the disease’s pathophysiology and recent biomarker development.

See Also:

"Current research and development (R&D) strategies in osteoarthritis are characterised by a trend towards developing new analgesics with novel mechanisms of action (MOAs), and drugs with disease-modifying effects, reflecting the market’s demand for such therapies," explains Herman.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Herman sees a substantial opportunity for pharmaceutical companies by supporting the efforts of academic institutions in identifying new disease targets and biomarkers, and in-licensing pipeline products with novel MOAs and disease-modifying potential.